期刊
BIOMOLECULES
卷 11, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/biom11030354
关键词
ER stress; unfolded protein response; integrated stress response; eIF2; Alzheimer's disease; Parkinson's disease; Huntington's disease; ALS
资金
- Israel Science Foundation Legacy Heritage Fund [2394/17]
With the extension of life span, there is an increasing burden of late-onset neurodegenerative diseases, for which effective treatments are lacking. Strategies to inhibit cellular toxicity and restore homeostasis are drawing increasing attention as gene therapy approaches face difficulties in tackling these diseases. Both inhibition and activation of the PERK pathway have shown benefits in disease models, but the complexity of the pathway and its effects on cell survival or death have led to conflicting results.
With the extension of life span in recent decades, there is an increasing burden of late-onset neurodegenerative diseases, for which effective treatments are lacking. Neurodegenerative diseases include the widespread Alzheimer's disease (AD) and Parkinson's disease (PD), the less frequent Huntington's disease (HD) and Amyotrophic Lateral Sclerosis (ALS) and also rare early-onset diseases linked to mutations that cause protein aggregation or loss of function in genes that maintain protein homeostasis. The difficulties in applying gene therapy approaches to tackle these diseases is drawing increasing attention to strategies that aim to inhibit cellular toxicity and restore homeostasis by intervening in cellular pathways. These include the unfolded protein response (UPR), activated in response to endoplasmic reticulum (ER) stress, a cellular affliction that is shared by these diseases. Special focus is turned to the PKR-like ER kinase (PERK) pathway of the UPR as a target for intervention. However, the complexity of the pathway and its ability to promote cell survival or death, depending on ER stress resolution, has led to some confusion in conflicting studies. Both inhibition and activation of the PERK pathway have been reported to be beneficial in disease models, although there are also some reports where they are counterproductive. Although with the current knowledge a definitive answer cannot be given on whether it is better to activate or to inhibit the pathway, the most encouraging strategies appear to rely on boosting some steps without compromising downstream recovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据